General
Preferred name
CEFEPIME
Synonyms
BMY-28142 ()
CEFEPIME HYDROCHLORIDE ()
Cefepima ()
VNRX-5022 ()
Renapime ()
J01DE01 ()
P&D ID
PD009507
CAS
88040-23-7
Tags
available
drug
Approved by
FDA
First approval
1996
Drug indication
Bacterial infection
Urinary tract infection
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, with greater activity against both than third-generation antibiotics. Cefepime has good activity against important pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Enterobacteriaceae, and multiple drug resistant Streptococcus pneumoniae. Whereas other cephalosporins are degraded by many plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and is a front line agent when infection with Enterobacteriaceae is known or suspected
DESCRIPTION Cefepime (BMY-28142) is a broad-spectrum and cross the blood-brain barrier cephalosporin. Cefepime shows antibacterial effects against both Gram-positive and Gram-negative aerobic bacteria. Cefepime induces neurotoxicity[1][2][3][4].
PRICE 29
DESCRIPTION Cefepime is a semisynthetic, broad-spectrum, fourth-generation cephalosporin antibacterial . It was removed from the World Health Organization's List of Essential Medicines in 2019. (GtoPdb)
DESCRIPTION Cefepime (BMY-28142) is a cephalosporin antibiotic with antimicrobial activity, induces neurotoxicity, inhibits both Gram-positive and Gram-negative, and can be used in the study of anaerobic bacteria. (TargetMol Bioactive Compound Library)
Compound Sets
13
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
ReFrame library
TargetMol Bioactive Compound Library
External IDs
94
Properties
(calculated by RDKit )
Molecular Weight
480.12
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
4
Aromatic Ring Count
1
cLogP
-1.28
TPSA
150.04
Fraction CSP3
0.53
Chiral centers
2.0
Largest ring
6.0
QED
0.21
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
antibiotic
Antibacterial
Bacterial
GABA Receptor
Pathway
Microbiology/virology
Anti-infection
Membrane Transporter/Ion Channel
Neuronal Signaling
Therapeutic Class
Antibiotics
Source data